Replies to post #45800 on Savvy Trades and Investments

[2morrowsGains]

SRTS...New presentation available...Robotic Intra-Operative Radio-Therapy System (IORT) has been named "Silhouette". FDA approval is expected by mid-year and could/will have a big impact on how breast cancer is treated (IMO).
Also, Sensus is introducing new products for tattoo removal, hair removal, acne lesion correction, pigmentation treatment, large pore treatment. and anti-aging.
http://investors.sensushealthcare.com/download/SRTS+presentation+-+MARCH+2018.pdf

Investment Highlights:
- Safe, effective, patented and reimbursed, offering multiple benefits:
- Patient benefits: Excellent clinical outcomes and superior aesthetics
- Physician benefits: Products build practices and improve efficiencies, retain patients and increase the number of visits; excellent ROI
- Payor benefits: Usually less costly than Mohs since no reconstructive or wound care costs
- Large U.S. market with OUS and pipeline opportunities
- Direct sales in U.S., distribution partnership in China
- Targeting clearances in Latin American and Asian countries
- Plans to broaden SRT indications to include psoriasis and intraoperative radiation therapy (IORT) for breast and other cancers
- A clearly-defined customer base to treat a rapidly-growing patient population, both in the U.S. and OUS
- Over 39% year over year revenue growth to $20.6M in 2017; high-60%s gross margin
- Strong balance sheet, with $11.2M cash, cash equivalents and investments and no long-term debt as of December 31, 2017
? Executive team has strong record with capital equipment models